

Sun Pharmaceutical Industries Ltd.,  
SUN HOUSE, CTS No. 201 B/1,  
Western Express HI Highway, Goregaon(E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**13 August 2022.**

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

BSE Limited,  
Market Operations Dept.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sirs,

**Sub: Update on Halol facility**

This is with respect to our communication dated May 10, 2022 regarding the US FDA inspection at the Company's Halol (Gujarat) facility from April 26 to May 9, 2022 and issuance of Form-483 by US FDA with 10 observations.

We now wish to inform you that the Company has received a communication from the US FDA indicating the inspection classification as "Official Action Indicated" (OAI). The OAI classification implies inter-alia that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved. The Company continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.

Sun Pharma continues to cooperate with the US FDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company's remedial action.

Sun Pharma remains committed to being GMP compliant and in supplying high-quality products to its customers and patients globally.

This is for your information and dissemination.

Thanking you,

Yours faithfully,  
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary & Compliance Officer**